Is the drug industry wrong about Alzheimer’s disease? Can cryptocurrency fund actual science? And should you feel sorry for Big Pharma?
We discuss all that and more on the latest episode of “The Readout LOUD,” STAT’s biotech podcast. First, we discuss the latest setback in the quest to find a treatment for Alzheimer’s and pick apart what it does and doesn’t mean for biotech’s best near-term hope. Then, we talk about one company’s mission to pay for drug development by issuing its own cryptocurrency, which is either a revolutionary development or a sign that biotech is running out of plot twists. And then STAT’s Ed Silverman joins us to break down what has been a rocky start to the year for Big Pharma, which is facing declining fortunes, frustrated investors, and a gathering storm in Washington. Finally, we’ll take stock of the surprisingly large number of emerging unicorns in health care, not of all whom like transparency.
For more on what we cover, here’s the news in Alzheimer’s; here’s more on the crypto thing; and here’s a look at unicorn transparency.
We’ll be back next Thursday evening — and every Thursday evening — so be sure to sign up on iTunes, Stitcher, Google Play, or wherever you get your podcasts.
And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email firstname.lastname@example.org.
Interested in sponsoring a future episode of “The Readout LOUD”? Email us at email@example.com.